Case Studies

Early Biomarkers for Insulin Resistance


Early detection of pre-diabetes has important implications for patient care and drug discovery. Metabolon’s technology is uniquely positioned to identify biomarkers, accelerate MOA, further personalized medicine and tailor therapy approaches.


A recent study in The Lancet determined that 347 million adults are affected by diabetes. Current methodology for measuring insulin resistance (IR) is limited and lacks early detection capabilities.


Download Case Studies